- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07941856
A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units
Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Unit Settings: A Mixed-Method Study
This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Shuo Li, M.D.
- Telefonnummer: +86-13671275323
- E-post: shuoli_bjmu@126.com
Studer Kontakt Backup
- Navn: Xi Yao, MMSc
- Telefonnummer: +86-13811429675
- E-post: yaoxi@pku.edu.cn
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100034
- Rekruttering
- Peking University First Hospital
-
Ta kontakt med:
- Shuo Li, M.D.
- Telefonnummer: +86-13671275323
- E-post: shuoli_bjmu@126.com
-
Ta kontakt med:
- Xi Yao, MMSc
- Telefonnummer: +86-13811429675
- E-post: yaoxi@pku.edu.cn
-
Hovedetterforsker:
- Liuyi Li, MMSc
-
Hovedetterforsker:
- Hongling Chu, Ph.D.
-
Hovedetterforsker:
- Xi Yao, MMSc
-
Underetterforsker:
- Meihua Hu, MMSc
-
Underetterforsker:
- Yuan Cheng, M.D.
-
Underetterforsker:
- Tian Sang, M.D.
-
Underetterforsker:
- Cui Yuan, MMSc
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
- Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
- Generates central-line-days within study observation window
Exclusion Criteria:
- CVC placed in external hospitals and not managed within the three participating ICUs
- Central-line-days generated outside study observation period
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: CLABSI Prevention Bundle Intervention Arm
Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out |
A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CLABSI incidence rate
Tidsramme: Baseline through intervention period, up to 36 months
|
CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU. |
Baseline through intervention period, up to 36 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall CLABSI prevention bundle adherence score
Tidsramme: Baseline through implementation period, up to 36 months
|
A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%. |
Baseline through implementation period, up to 36 months
|
|
Acceptability of the CLABSI prevention intervention bundle
Tidsramme: Entire study duration, up to 36 months
|
Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Quantitative assessment
Tidsramme: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Qualitative assessment
Tidsramme: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes. |
Entire study duration, up to 36 months
|
|
Feasibility of implementation of the intervention bundle
Tidsramme: Entire study duration, up to 36 months
|
Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Quantitative assessment
Tidsramme: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Qualitative assessment
Tidsramme: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes. |
Entire study duration, up to 36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Shuo Li, M.D., Peking University First Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2024-197-002
- 23-515 (Annet stipend/finansieringsnummer: China Medical Board)
- 2024研197-002 (Annen identifikator: Peking University First Hospital Ethics Committee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .